Corpuls Showcases New Medical Devices at Texas Conference
The manufacturer presents an in-ear monitor and mechanical CPR system for potential introduction into the U.S. market.
Updated on Oct. 29, 2026 in Heart Disease
Live Poll
Should the U.S. accelerate the regulatory approval process for medical technologies already approved in other countries?
Corpuls introduced its corpuls auryx in-ear vital-signs monitor and corpuls cpr mechanical compression device at the Air Medical Transport Conference in Fort Worth, Texas. The company is currently seeking FDA authorization for these tools before beginning sales in the United States.
Why it matters
Showcasing this equipment at a major medical conference allows Corpuls to familiarize American emergency providers with its technology ahead of a planned domestic launch. The devices offer advanced monitoring and automated life-support capabilities currently utilized in other global markets.
The corpuls auryx sensor weighs 8.6 grams and operates for over 10 hours, while the corpuls cpr unit weighs 5.5 kilograms and provides adjustable compression rates between 80 and 120 per minute for 90 minutes on a charge. These tools are currently in use across 75 countries.
The players
Corpuls
Headquartered in Kaufering, Germany, this company is a manufacturer of medical technology for emergency services.
The details
The corpuls auryx uses a three-axis accelerometer to track metrics including pulse rate, SpO2, and body temperature, transmitting data via Bluetooth to a mobile device. The corpuls cpr system utilizes an adjustable arm and compression pad to deliver automated chest compressions at varying depths.
Timeline
August 2026: The corpuls auryx entered the international market.
October 2026: Products were introduced at the AMTC in Texas.
The Big Picture
The company's expansion into the U.S. healthcare sector is contingent on successfully completing the FDA medical device authorization process. This transition follows the established regulatory pathways required for any international manufacturer seeking to supply specialized life-support hardware to domestic providers.
If approved, these devices could improve the speed and precision of vital-sign monitoring and mechanical chest compressions during emergency transport. The automated system aims to provide consistent compression rates, potentially enhancing the standard of care for patients suffering cardiac events.
The takeaway
Advancements in mechanical CPR and portable monitoring represent a shift toward more compact, data-driven emergency tools. Healthcare providers should stay updated on regulatory approvals that may soon influence the availability of specialized equipment in their regions.
Further reading
For more on cardiovascular care technology, visit Heart Disease.
Source note: This article includes information reported by Vertical Mag.
Live Poll
Should the U.S. accelerate the regulatory approval process for medical technologies already approved in other countries?
